NERVMICRO

Minerva Neurosciences, Inc.

HealthcareBiotechnology
$4.92
$0.00(-3.53%)
52W$1.59
$12.46
Updated Jul 7, 02:00 AM
RSI54
RS Rating37/99
Beta1.57
Volatility97%
F-Score2/9
Mkt Cap$34M
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

Minerva Neurosciences, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 37), showing significant lag compared to the market leaders. Earnings contraction of 154% provides fundamental context to the price action. Investors should exercise caution due to high volatility (97% annualized), which requires wider risk management.

Relative Strength
37
out of 99
Lagging
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
1.57
vs S&P 500
HIGH BETA
52W Position
31%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$5.22
50 SMA > 100 SMA$5.87
100 SMA > 150 SMA$5.30
150 SMA > 200 SMA$4.80

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$4.68+5.22%ABOVE
50 SMA$5.22-5.80%BELOW
100 SMA$5.87-16.21%BELOW
150 SMA$5.30-7.19%BELOW
200 SMA$4.80+2.50%ABOVE

Price Performance

1D-3.5%
1W-9.4%
1M+6.3%
3M-5.9%
6M+13.9%
YTD+25.5%
1Y+200.0%
3Y-21.7%
52-Week Trading Range31% from low
$4.92
52W Low$1.59
52W High$12.46

Technical Indicators

RSI (14)NEUTRAL
53.7
305070
Setup ScoreCOOL
1/10
Base depth: 72.1%

Risk Profile

Beta
1.57
52W Vol
97%
ATR
$0.47
Max DD (1Y)
-49%

Volume Analysis

Today
224.9K
50D Avg
138.4K
Vol Ratio
1.63x
Liquidity
ILLIQUID

Earnings Momentum

Q2'25+62%
$-0.43
Q3'25+67%
$-0.36
Q4'25-959%
$-25.51
Q1'26-411%
$-2.86
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth

10 Years:-14.13%
5 Years:
3 Years:
TTM:-154.47%

Stock Price CAGR

10 Years:-24.75%
5 Years:-23.32%
3 Years:-21.68%
1 Year:+200.00%

Return on Equity

10Y Avg:-65.4%
5Y Avg:-164.6%
3Y Avg:
Last Year:

Key Metrics

Market Cap$34M
Gross Margin
Net Margin
Piotroski F-Score2/9

Frequently Asked Questions

Is NERV in an uptrend right now?

NERV has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is NERV overbought or oversold?

NERV's RSI (14) is 54. The stock is in neutral territory, neither overbought nor oversold.

Is NERV outperforming the market?

NERV has a Relative Strength (RS) Rating of 37 out of 99. NERV is currently lagging the broader market.

Where is NERV in its 52-week range?

NERV is trading at $4.92, which is 39% of its 52-week high ($12.46) and 31% above its 52-week low ($1.59).

How volatile is NERV?

NERV has a Beta of 1.57 and 52-week volatility of 97%. It's more volatile than the S&P 500 - expect bigger swings.

Disclaimer: Data is for informational purposes only. May be delayed or contain errors. Past performance does not guarantee future results. This is not financial advice. Always conduct your own research and consult professionals before making investment decisions.